{
  "docId": "019de073-42e0-708e-bbdb-4616fa343de3",
  "docSlug": "252a92bcbab8bda657ee7494bf765251",
  "documentTitle": "BioAtla | Investor Presentation Deck | 37 slides",
  "authorId": "bioatla",
  "authorName": "BioAtla",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 31,
  "pageCount": 37,
  "prevPage": 30,
  "nextPage": 32,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "dense",
  "nDataPoints": 14,
  "notes": "The slide uses a timeline-based visual to show dose escalation steps leading to RP2D selection.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-42e0-708e-bbdb-4616fa343de3/31",
  "deckHref": "/decks/019de073-42e0-708e-bbdb-4616fa343de3",
  "deckJsonHref": "/decks/019de073-42e0-708e-bbdb-4616fa343de3.json",
  "deckAnchorHref": "/decks/019de073-42e0-708e-bbdb-4616fa343de3#slide-31",
  "components": [
    {
      "bbox": {
        "h": 0.45,
        "w": 0.6,
        "x": 0.05,
        "y": 0.22
      },
      "kind": "chart",
      "text": "Dose escalation timeline for BA3071",
      "attrs": null,
      "subkind": "timeline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bb62b3fb-5dea-44fe-b3b1-5f1f4450048b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.3,
        "x": 0.05,
        "y": 0.67
      },
      "kind": "legend",
      "text": "BA3071 monotherapy; BA3071 in combination with nivolumab",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1b3d066e-42b3-421a-bde1-91b46e8fa2a2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.15,
        "x": 0.712,
        "y": 0.365
      },
      "kind": "list",
      "text": "Possible Phase 2 Dose Expansion Cohorts: RCC, Melanoma, NSCLC, SCLC, Bladder, Gastric, aHCC, Cervical",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "006818c1-91f5-4582-875d-17d0c7b9f820",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.7,
        "x": 0.17,
        "y": 0.79
      },
      "kind": "list",
      "text": "Objectives: Determine Phase 2 dose and MTD; Characterize safety and clinical activity; Characterize PK, ADA and biomarkers",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "87215d5e-36ec-4435-b24d-be066f26f676",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.15,
        "x": 0.03,
        "y": 0.14
      },
      "kind": "title",
      "text": "A basket study",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "47bd698e-76e3-4c70-b88a-37e4ba80e10b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.03,
        "y": 0.08
      },
      "kind": "title",
      "text": "Phase 1/2 trial design for CAB-CTLA-4 Naked Antibody (BA3071)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5da268bd-3982-4935-8eea-373dbaf85647",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "timeline",
      "slug": null,
      "matchId": "745693fc-006d-43b1-b960-dc2e2122ae4b",
      "evidence": "Visual representation of clinical trial phases and dose escalation steps over time.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}